NCT06893016View on ClinicalTrials.gov

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

PHASE3RecruitingINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

June 15, 2026

Study Completion Date

September 15, 2026

Conditions
Obesity
Interventions
DRUG

RAY1225

RAY1225 will be administered SC

DRUG

Placebo

Placebo will be administered SC.

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY